News

News

  • December 16, 2017

    A new combination of antibiotics allows treating 60% of hospital-acquired pneumonia

    A study published in the journal The Lancet Infectious Diseases shows the ability of a new antibiotic (ceftazimida-avibactam) to treat hospital-acquired pneumonia, including ventilation-associated pneumonia. It has similar efficacy to one of the most used type of antibiotics in the treatment of this infection, carbapenems, but has the advantage of overcoming problems derived from its administration, such as the resistance of certain bacteria. Dr. Antoni Torres, Head of the Respiratory Intensive Surveillance Unit (UVIR) of the Hospital Clínic and head of the IDIBAPS team on Applied research in infectious respiratory diseases, critically ill patients and lung cancer, is the principal investigator of the study and first author of the article.

    Read the rest of this entry

  • October 26, 2017

    Computational Simulations Suggest Multiple Sclerosis is a Single Disease

    IDIBAPS researchers publish a study in the journal Plos Computational Biology that supports the idea that multiple sclerosis (MS), which has widely varying symptoms and progression in different patients, is nonetheless a single disease with common underlying mechanisms. Pablo Villoslada, Head of the IDIBAPS group Pathogenesis and new treatments in Multiple Sclerosis, has coordinated the study. Ekaterina Kotelnikova, researcher at the same group, is the first author.

    Read the rest of this entry

  • October 18, 2017

    Gisela Sugranyes awarded with a NARSAD Young Investigator Grant

    The Brain and Behaviour Research Foundation has awarded a research grant to Gisela Sugranyes, 50/50 researcher at the Multimodal neuroimaging in high risk and early psychosis IDIBAPS research team. The 'NARSAD 2017 Young Investigator Grant' is endowed with 70,000 for two years and is one of the most prestigious awards given to young researchers in the field of neuroscience. In this case, the funds will be used in the study of psychosis, specifically in determining the role played by an alteration in glutamatergic transmission in the clinical and cognitive manifestations of the disorder.

    Read the rest of this entry

  • October 9, 2017

    IDIBAPS researchers describe the mechanism by which SOX11 promotes relapses in mantle cell lymphoma

    Researchers at IDIBAPS publish an article in the Blood journal in which they show the mechanism by which the transcription factor SOX11 participates in the dissemination and aggressiveness of mantle cell lymphoma. They have discovered that SOX11 promotes the creation of a protective environment that ensures survival and resistance to treatments of tumor cells. The study was coordinated by Dr. Virginia Amador, researcher at the Human and experimental functional oncomorphology IDIBAPS team.

    Read the rest of this entry

  • June 12, 2017

    Aleix Prat, named Board Member of the Breast International Group

    Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has been named member of the Executive Board of the Breast International Group (BIG). The BIG is an international non-profit organisation that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. The appointment, which represents a recognition to his professional career in this field, took place during the annual meeting of the American Society of Clinical Oncology (ASCO) held in June 2-6 in Chicago.

    Read the rest of this entry

PreviousNext